I am a medical oncologist/hematologist who is a member of a close-knit team that provides compassionate, multidisciplinary care to patients with lymphoma. I have clinical expertise in Hodgkin Lymphoma, non-Hodgkin lymphoma and Chronic Lymphocytic Leukemia (CLL), and my research interests focus on finding new treatments for patients with these diseases. To accomplish this goal, I serve as the principal investigator on several clinical trials that evaluate promising new treatments from laboratories around the world. I have helped develop agents now approved to treat lymphoma and CLL, including bortezomib and ibrutinib. Many of my trials explore innovative ways to combine existing drugs with newer treatments in order to find novel ways to maximize responses while minimizing side effects in patients with lymphoma. I am also a member of the Developmental Therapeutics Group, a team of medical oncologists dedicated to providing access to the newest phase I agents for patients with all types of cancer throughout the Memorial Sloan Kettering.
- Clinical Expertise: Hodgkin and Non-Hodgkin Lymphomas; Clinical Trials and New Drug Development in Lymphoma and Solid Tumors
- Languages Spoken: English
- Education: MD, PhD, New York University School of Medicine
- Residencies: Hospital of the University of Pennsylvania
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by John F. Gerecitano
Clinical Trials Co-Investigated by John F. Gerecitano
- A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
- A Phase I Study of GSK2857916 in Patients with Recurrent or Persistent Multiple Myeloma
- A Phase I Study of RXDX-101 in Patients with Locally Advanced or Metastatic Cancers Containing Alternations in the TRKA, TRKB, TRKC, ROS1, or ALK Proteins
- A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma